Stockholm - Free Realtime Quote SEK

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

288.20

+9.00

+(3.22%)

As of 10:36:12 AM GMT+2. Market Open.

Sobi publishes Q1 2025 report: Portfolio continues to deliver

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2025

PR Newswire 2 hours ago

BIOVF

SWOBY
Sobi presents clinical data at WFH 2025 Comprehensive Care Summit

Sobi® (STO: SOBI) presents clinical data aimed at updating the global haemophilia community attending this year's WFH 2025 Comprehensive Care Summit in Dubai from the 23 – 25 April. New and updated outcomes and analyses will be presented from the XTEND phase 3clinical program testing the effectiveness of Altuvoct® (efanesoctocog alfa) treatment for haemophilia A, including updates on patients' joint health and surgical outcomes in patients.

PR Newswire 6 days ago

BIOVF

SWOBY
Invitation: Sobi's Q1 report

Sobi plans to publish its report for the first quarter of 2025 on 29 April 2025 at 08:00 CET.

PR Newswire 13 days ago

BIOVF

SWOBY
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Thursday, 8 May 2025 at 10.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.

PR Newswire 28 days ago

BIOVF

SWOBY
Sobi publishes Annual and sustainability report for 2024

Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 and how Sobi strives to identify and unlock potential breakthrough innovations that transform the lives of people with rare diseases.

PR Newswire 28 days ago

BIOVF

SWOBY
Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress

Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS) which is to be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress by Prof. Giamarellos-Bourboulis, from the Hellenic Institute for the Study of Sepsis. The study underscores Sobi's commitment to advancing medicine through targeted therapies for seve

PR Newswire last month

BIOVF

SWOBY
US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg)

Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. The application was granted Priority Review with a PDUFA date of June 27, 2025.

PR Newswire last month

BIOVF

SWOBY
EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN

Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments.

PR Newswire 2 months ago

BIOVF

SWOBY
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments. “C3G and IC-MPGN are severe and life-

GlobeNewswire 2 months ago

BIOVF

SWOBY

APLS
Sobi publishes Q4 2024 report: A solid ending to a strong year

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024.

PR Newswire 2 months ago

BIOVF

SWOBY
Invitation: Sobi's Q4 and FY 2024 report

Investors, analysts, and the media are invited to a conference call on the same day at 14:30 CET, 13:30 GMT, and 08:30 EST. The call will include a presentation of the results and a Q&A session.

PR Newswire 3 months ago

BIOVF

SWOBY
FDA accepts Sobi North America’s thrombocytopenia therapy sNDA

The sNDA is supported by data from the AVA-PED-301 trial.

Pharmaceutical Technology 4 months ago

SWOBY
Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia

Avatrombopag PDUFA date set for July 24, 2025WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for avatrombopag (DOPTELET®) for the treatment of thrombocytopenia in pediatric patients one year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient

GlobeNewswire 4 months ago

BIOVF

SWOBY
High Growth Tech Stocks To Watch This November 2024

As global markets navigate the uncertainties surrounding the incoming Trump administration, key indices like the S&P 500 and Nasdaq have experienced notable declines, reflecting investor caution amid potential policy shifts and inflationary pressures. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience through innovation and adaptability to evolving regulatory landscapes.

Simply Wall St. 5 months ago

BIOVF

SWOBY
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Wednesday, 11 December 2024 at 09.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden. Registration for the Meeting will begin at 08.30.

PR Newswire 5 months ago

BIOVF

SWOBY
Sobi to present new data across its immunology portfolio at the ACR Convergence 2024

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of four abstracts that highlights data from its immunology portfolio at the ACR Convergence 2024 taking place in Washington, D.C. from November 14–19, 2024. Sobi’s commitment to delivering innovative treatments for people living with immunological diseases is seen in global studies spanning multiple disorders: Results from two

GlobeNewswire 5 months ago

BIOVF

SWOBY
David Meek is proposed as new Chair of the Board of Directors of Sobi

David Meek currently serves as a member of the Board of Directors of Cullinan Therapeutics, uniQure (Chair) and the University of Southern California School of Pharmacy and Pharmaceutical Sciences. He also has previous experience from board work in listed pharmaceutical companies and US and European trade associations. David Meek has extensive experience from senior positions in the international pharmaceutical industry. Most recently he served as Chief Executive Officer and Board Director of Mi

PR Newswire 5 months ago

BIOVF

SWOBY
New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference

Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still's disease (AOSD) who had an inadequate response to high-dose glucocorticoids (GCs) will be presented at the American College of Rheumatology (ACR) Convergence in Washington D.C. The data were pooled from two open-label, single-arm interventional studies, the phas

PR Newswire 5 months ago

BIOVF

SWOBY
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today announced that detailed data from the phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the 2024 American Society of Nephrology (ASN) Kidney Week. The results highlighted the potential of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, debilitating kidney dise

PR Newswire 5 months ago

BIOVF

SWOBY
Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call

VALIANT Phase 3 results after presentation at ASN

PR Newswire 5 months ago

BIOVF

SWOBY

Performance Overview

Return	SOBI.ST	OMX Stockholm 30 Index (^OMX)
YTD	-9.20%	-2.25%
1-Year	+1.69%	-5.44%
3-Year	+45.41%	+17.89%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Sobi publishes Q1 2025 report: Portfolio continues to deliver

Sobi presents clinical data at WFH 2025 Comprehensive Care Summit

Invitation: Sobi's Q1 report

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

Sobi publishes Annual and sustainability report for 2024

Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress

US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg)

EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Sobi publishes Q4 2024 report: A solid ending to a strong year

Invitation: Sobi's Q4 and FY 2024 report

FDA accepts Sobi North America’s thrombocytopenia therapy sNDA

Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia

High Growth Tech Stocks To Watch This November 2024

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

Sobi to present new data across its immunology portfolio at the ACR Convergence 2024

David Meek is proposed as new Chair of the Board of Directors of Sobi

New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference

Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN

Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call

Performance Overview